



AT THE HELM

Peter Kenney, partner; Patty Henhoeffer, managing director; Rick Sannem, partner

PERFORMANCE

Agency experienced a sharp spike in business

HIGHLIGHTS

Landed Endocyte as first client in the oncology space

Snagged business from Wellspring Pharmaceutical, Similasan and Monistat

Headcount up from 35 to 53 in two years

CHALLENGES

Lost work from Alcon Canada and Biomers

For contact details, service offerings and client roster, see Agency A-to-Z, beginning on page 187

“That new consumer journey... is the type of assignment that really gets us going”

—Peter Kenney

DiD

Philly-area firm expands its range, its client base—and its office space



DiD's growth—from 35 full-timers at this time two years ago to 53 now, plus another dozen contractors who are in the office more than they're not—is, by most measures, a very good thing. But that sharp spike in business and headcount left everyone at the suburban Philly firm feeling cramped.

So in April the agency moved from one quirky workspace (a renovated hotel that DiD partner Peter Kenney calls “a rabbit warren of little rooms”) to another (a renovated power plant dating back to the 1880s). The old space had closed doors aplenty; the new one is all glass and open space, complete with 24-foot ceilings. “What we have now is something that’s more reflective of our team approach,” Kenney says.

The new space has proximity to a big client—McNeil Consumer Healthcare is practically within shouting distance—and to mass transportation. “We overlook the train lines, which should help us in terms of attracting talent,” says managing director Patty Henhoeffer.

The office upgrade was one of several for-the-better changes that DiD has experienced over the last year or so. To ease the day-to-day management burden on Kenney and fellow partner Rick Sannem, DiD restructured

and expanded its leadership team. It elevated three staffers into new roles: Elyse Cole (VP, strategy and strategic services), Bill Fay (director, client services) and Abby Galardi (director, creative services).

“There were a lot of things that weren’t getting done because Rick and I were off working with clients,” Kenney admits. “These were three people who had gained loads of respect and were chomping at the bit for more responsibility. It was a logical transition.”

DiD expanded into new therapeutic areas. Endocyte became DiD’s first client in the oncology space (on a drug for ovarian cancer). Interleukin Genetics gave the agency a foothold in personalized medicine (on a product that determines disposition for periodontal disease). Business came from WellSpring Pharmaceutical (for heartburn drug Gelusil) and homeopathic product supplier Similasan. Yeast infection drug Monistat returned after years away. “It kind of wandered back,” Kenney cracks.

“With my condition, does it matter which pain reliever I take?”

Your patients may not know the difference between acetaminophen and NSAIDs. And that may have unintended consequences.

- TYLENOL® does not interfere with aspirin's cardioprotective mechanism the way ibuprofen can.*
- TYLENOL® does not cause GI irritation the way that aspirin, naproxen sodium, or even ibuprofen can.*
- TYLENOL®, when taken at recommended doses, does not compromise renal function in patients with existing kidney dysfunction the way NSAIDs can.†

Let them know
TYLENOL® is different.

Order FREE TYLENOL® samples at TylenolProfessional.com or scan this code now

TYLENOL® A Difference Worth Discussing

REFERENCES: 1. Conolly Lamm F, Kelly MP, Kaplan SC, et al. Cyclooxygenase inhibitors and the aspirin effect of aspirin. *N Engl J Med*. 2003;349(26):2618-2627. 2. Saito H, et al. The effect of aspirin on platelet aggregation and the risk of gastrointestinal bleeding. *Gastroenterology*. 2002;122(5):1412-1418. 3. Henrichs J, et al. Tylenol Professional. 4. The Pharmacology of analgesic and antipyretic drugs with special reference to their use in clinical practice. *Textbook of Pharmacology*. 1991;11(1):31-38. 5. Sagar P. Renal effects and contraindications of NSAIDs for routine pain management: path to renal protection in practice. *Endocrine*. 2008;30(2):100-105. 6. www.fda.gov/oc/ohrt/tylenol.html

DiD work for the Tylenol Kids' Wellness Tracker App (above left) and a Tylenol professional ad (above)

DiD had frustrations as well. Owing to a conflict with client Bausch & Lomb, the firm no longer works with Alcon Canada. Its work on behalf of Biomers failed to evolve due to funding issues. “We invested a lot in some clients who never had the resources to execute anything,” is the way Kenney puts it.

Expansion into other therapeutic areas is on the to-do list, with Henhoeffer pointing to skin care and animal health as likely targets: “They seem the natural next step.” Kenney, for his part, hopes the relationship with McNeil will intensify even further. “That new consumer journey they’re on, with social and search and so many other components—that’s the type of assignment that really gets us going.” —Larry Dobrow